Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
0.00%
)
US TECH 100
24,022.40
(
0.03%
)
Dow Jones
46,946.41
(
0.00%
)
Brent Oil
99.95
(
1.67%
)
Bitcoin
73,820.48
(
-1.37%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Biowatch post# 52388

Wednesday, 07/10/2013 2:19:00 PM

Wednesday, July 10, 2013 2:19:00 PM

Post# of 257251
XTLB will once again trade on Nasdaq:

http://finance.yahoo.com/news/xtl-biopharmaceuticals-returns-nasdaq-174500572.html

XTLB once considered itself a player in HCV; some of its HCV drugs failed in early clinical trials (#msg-20222352), while an NS5A inhibitor was sold to Presidio Pharma in 2008 (#msg-27791536) and turned up in 2010 as PPI-461 (#msg-52296077). PPI-461 was shelved and superseded by a newer NS5A drug called PPI-668 (#msg-76993511).

One XTLB ADR will be equivalent to 20 home-market shares on the TASE in Israel.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now